NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Lexicon Pharmaceuticals, Inc. (LXRX) Stock Analysis

Lexicon Pharmaceuticals, Inc. (LXRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

LXRX

$2.24

−$0.02 (−0.88%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LXRX with… →

LXRX Key Statistics

As of Sep 4, 2026
Trading
Open
$2.25
Previous Close
$2.26
Day's Range
2.22–2.26
52-Week Range
1.05–2.68
Volume
1.04M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.03
Valuation
Market Cap
$996.70M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
−13.77
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
24.03
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.16
Financials (FY)
Revenue (FY)
$49.80M+60.24%
Net Income (FY)
−$50.34M
Profit marginThe share of revenue left as profit after all costs and taxes.
−147.38%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
444.96M
1-Year Return
+109.35%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
3.36M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LXRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+94.78%
2025+55.41%
2024−51.63%
2023−19.90%
2022−51.52%
2021+15.20%
2020−17.59%
2019−37.50%
2018−32.79%
2017−28.56%
2016 (partial year)−13.51%

As of September 4, 2026.

LXRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$49.80M−$50.34M−101.1%
2024$31.08M−$200.40M−644.8%
2023$1.20M−$177.12M−14710.9%
2022$139.00K−$101.94M−73341.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$49.80M$49.53M−$48.91M−$50.34M−101.1%
2024$31.08M$30.47M−$197.12M−$200.40M−644.8%
2023$1.20M$1.12M−$171.75M−$177.12M−14710.9%
2022$139.00K$139.00K−$100.76M−$101.94M−73341.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LXRX Valuation vs Biotechnology Median

Median of 656 stocks
MetricLXRXBiotechnology medianvs median
P/S ratio24.0315.2657% above
Profit margin−147.38%0.00%147.4 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Lexicon Pharmaceuticals, Inc. (LXRX) is capitalised at $996.70M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 81.

The most recent close on file for LXRX is $2.24, dated September 4, 2026. That is −$0.02 (−0.88%) against the previous close. The 52-week range on file runs from $1.05 to $2.68. The latest close sits 113.33% above that 52-week low.

Financial Health

In fiscal 2025, Lexicon Pharmaceuticals, Inc. reported revenue of $49.80M. Against the prior fiscal year total of $31.08M, that is a change of +60.24%. The same year closed with a net loss of $50.34M. The reported profit margin is −147.38%. That is 147.4 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.16.

Across the 4 fiscal years on file, revenue moves from $139.00K in 2022 to $49.80M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads −13.77. The price-to-sales ratio is 24.03. On price-to-sales that is 57.47% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned +109.35%. Across 10 years the annualized return works out at −16.87%. The reported beta is 1.03. Annualized volatility over the trailing 10 years is 97.39%.

Growth & Income

No dividend is on file for LXRX.

2026 is still running; the price is +94.78% year to date. Across the complete calendar years on file, 2025 returned +55.41% and 2024 returned −51.63%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Lexicon Pharmaceuticals, Inc. (LXRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lexicon Pharmaceuticals, Inc. LXRX $996.70M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Lexicon Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Visit website →